Nutter Carol Acquires 875 Shares of Claritev (NYSE:CTEV) Stock

Claritev (NYSE:CTEV) SVP Nutter Carol bought 875 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was bought at an average price of $28.41 per share, for a total transaction of $24,858.75. Following the completion of the purchase, the senior vice president directly owned 46,941 shares of the company’s stock, valued at $1,333,593.81. The trade was a 1.90% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Claritev Stock Up 4.2%

CTEV stock traded up $1.20 during mid-day trading on Wednesday, reaching $29.55. The company had a trading volume of 82,852 shares, compared to its average volume of 182,812. The stock has a market capitalization of $503.83 million, a P/E ratio of -1.71 and a beta of 0.77. Claritev has a one year low of $11.50 and a one year high of $74.07. The stock’s 50-day simple moving average is $22.08 and its two-hundred day simple moving average is $26.85.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CTEV shares. Guggenheim reiterated a “buy” rating on shares of Claritev in a research note on Tuesday, February 24th. Citigroup reiterated a “buy” rating on shares of Claritev in a research note on Wednesday, May 13th. Wall Street Zen cut Claritev from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Canaccord Genuity Group started coverage on Claritev in a research note on Friday, May 29th. They issued a “buy” rating and a $32.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Claritev in a research note on Friday, March 27th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $33.67.

Institutional Investors Weigh In On Claritev

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. H&F Corporate Investors VIII Ltd. bought a new stake in shares of Claritev during the third quarter valued at about $285,988,000. Arini Captial Management Ltd acquired a new position in Claritev during the fourth quarter worth about $64,291,000. Public Investment Fund acquired a new position in Claritev during the third quarter worth about $68,009,000. Beach Point Capital Management LP grew its holdings in Claritev by 77.4% during the fourth quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock worth $32,276,000 after acquiring an additional 329,424 shares during the period. Finally, Vanguard Group Inc. acquired a new position in Claritev during the third quarter worth about $27,483,000. 87.15% of the stock is currently owned by institutional investors.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.